Alixorexton for the Treatment of Narcolepsy Type 2: Insights From SLEEP 2026

CONFERENCE REPORTER

Alkermes today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2).¹ Richard K. Bogan, MD, sat down with Psychiatric Times to discuss the data.

Alixorexton is a novel, investigational, oral, selective orexin 2 receptor agonist in development for narcolepsy type 1 (NT1), NT2, and idiopathic hypersomnia.

Once-daily alixorexton met the study’s 2 primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared with placebo on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 8 in adults with NT2 (N=93). Patient-reported improvements in wakefulness were sustained through the 5-week open-label extension. 

Alixorexton also demonstrated clinically meaningful improvements across exploratory patient-reported outcomes (PROs) measuring fatigue and cognition. As to safety and tolerability profile, alixorexton was generally well tolerated at all doses tested (10 mg, 14 mg, and 18 mg).  

Topline results from the Vibrance-2 study were previously announced in November 2025.²

Dr Bogan is an associate clinical professor at the University of South Carolina School of Medicine and an associate clinical professor at the Medical University of South Carolina in Charleston.

References

1. Alkermes presents detailed positive results from Vibrance-2 phase 2 study of alixorexton in adults with narcolepsy type 2 at SLEEP 2026. News release. June 16, 2026. Accessed June 16, 2026.

2. Kuntz L. Alixorexton for treatment of narcolepsy type 2: new positive phase 2 data. Psychiatric Times. November 13, 2025. https://www.psychiatrictimes.com/view/alixorexton-for-treatment-of-narcolepsy-type-2-new-positive-phase-2-data